Serum levels of adhesion molecules ICAM-1 and VCAM-1 and tissue inhibitor of metalloproteinases, TIMP-1, are elevated in patients with autoimmune thyroid disorders: Relevance to vascular inflammation

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 10, 2011, Pages 817-822

  Jublanc, C ^a   Beaudeux, J L ^b   Aubart, F ^c   Raphael, M ^c   Chadarevian, R ^a   Chapman, M J ^c,d,e   Bonnefont Rousselot, D ^c,f   Bruckert, E ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL CHARLES FOIX   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e INSERM   (France)

^f Laboratoire de Biologie de la Nutrition EA2498   (France)

Author keywords

Adhesion molecules; Autoimmunity; Metalloproteinases; Thyroid disorders; Vascular inflammation

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BLOOD; FEMALE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOLOGY; MALE; MIDDLE AGED; PROSPECTIVE STUDY; THYROID DISEASE;

ADULT; AGED; AUTOIMMUNE DISEASES; FEMALE; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THYROID DISEASES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASCULAR CELL ADHESION MOLECULE-1;

EID: 80053050816     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.02.023     Document Type: Article

References (29)

1. Abou-Raya A., Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006, 5:331-337.
2. Forstegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005, 25:1776-1785.
3. Libby P. Atherosclerosis: the new view. Sci Am 2002, 286:46-55.
4. Miyazaki A., Mirakian R., Bottazzo G.F. Adhesion molecule expression in Graves' thyroid glands; potential relevance of granule membrane protein (GMP-140) and intercellular adhesion molecule-1 (ICAM-1) in the homing and antigen presentation processes. Clin Exp Immunol 1992, 89:52-57.
5. Marazuela M., Postigo A.A., Acevedo A., Diaz-Gonzalez F., Sanchez-Madrid F., de Landazuri M.O. Adhesion molecules from the LFA-1/ICAM-1, 3 and VLA-4/VCAM-1 pathways on T lymphocytes and vascular endothelium in Graves' and Hashimoto's thyroid glands. Eur J Immunol 1994, 24:2483-2490.
6. Nakashima M., Eguchi K., Ida H., Yamashita I., Sakai M., Origuchi T., et al. The expression of adhesion molecules in thyroid glands from patients with Graves' disease. Thyroid 1994, 4:19-25.
7. Pesce G., Fiorino N., Riccio A.M., Montagna P., Torre G., Salmaso C., et al. Different intrathyroid expression of intercellular adhesion molecule-1 (ICAM-1) in Hashimoto's thyroiditis and Graves' disease: analysis at mRNA level and association with B7.1 costimulatory molecule. J Endocrinol Invest 2002, 3:289-295.
8. Ciampolillo A., Napolitano G., Mirakian R., Miyasaki A., Giorgino R., Bottazzo G.F. Intercellular adhesion molecule-1 (ICAM-1) in Graves' disease: contrast between in vivo and in vitro results. Clin Exp Immunol 1993, 94:478-485.
9. Heufelder A.E., Bahn R.S. Elevated expression in situ of selectin and immunoglobulin superfamily type adhesion molecules in retroocular connective tissues from patients with Graves' ophthalmopathy. Clin Exp Immunol 1993, 91:381-389.
10. Pappa A., Calder V., Fells P., Lightman S. Adhesion molecule expression in vivo on extraocular muscles (EOM) in thyroid-associated ophthalmopathy (TAO). Clin Exp Immunol 1997, 108:309-313.
11. Heufelder A.E., Bahn R.S. Soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' ophthalmopathy and thyroid diseases. Clin Exp Immunol 1993, 92:296-302.
12. De Bellis A., Bizzarro A., Gattoni A., Romano C., Di Martino S., Sinisi A.A., et al. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma. J Clin Endocrinol Metab 1995, 80:2118-2121.
13. Wenisch C., Myskiw D., Gessl A., Graninger W. Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism. J Clin Endocrinol Metab 1995, 80:2122-2126.
14. Fukazawa H., Yoshida K., Kaise N., Kiso Y., Sayama N., Mori K., et al. Intercellular adhesion molecule-1 (ICAM-1) in the sera of patients with Graves' disease: correlation with disease activity and treatment status. Thyroid 1995, 5:373-377.
15. Ozata M., Bolu E., Sengul A., Altinsoy H.I., Turan M., Corakci A., et al. Soluble intercellular adhesion molecule-1 concentrations in patients with subacute thyroiditis and in patients with Graves' disease with or without ophthalmopathy. Endocrinol Jpn 1996, 43:517-525.
16. De Bellis A., Di Martino S., Fiordelisi F., Muccitelli V.I., Sinisi A.A., Abbate G.F., et al. Soluble intercellular adhesion molecule-1 (ICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy. J Clin Endocrinol Metab 1998, 83:1222-1225.
17. Sonnet E., Massart C., Gibassier J., Allannic H., Maugendre D. Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease. J Endocrinol Invest 1999, 22:430-435.
18. Myśliwiec J., Kretowski A., Szelachowska M., Topolska J., Mikita A., Kinalska I. Serum l-selectin and ICAM-1 in patients with Graves' ophthalmopathy during treatment with corticosteroids. Immunol Lett 2001, 78:123-126.
19. Lu M., Fang P., Zhang Z., He H., Gao S., Hou B., et al. A preliminary clinical application of ICAM-1 RIA in three kinds of thyroid disease. Chin Med J (Engl) 2002, 115:1552-1555.
20. Ozata M., Bolu E., Sengul A., Tasar M., Beyhan Z., Corakci A., et al. Effects of octreotide treatment on Graves' ophthalmopathy and circulating ICAM-1 levels. Thyroid 1996, 6:283-288.
21. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002, 115(Pt 19):3719-3727.
22. Beaudeux J.L., Giral P., Bruckert E., Foglietti M.J., Chapman M.J. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004, 42:121-131.
23. Fiedorczyk M., Klimiuk P.A., Sierakowski S., Gindzienska-Sieskiewicz E., Chwiecko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J Rheumatol 2006, 33:1523-1529.
24. Perez P., Kwon Y.J., Alliende C., Leyton L., Aguilera S., Molina C., et al. Increased acinar damage of salivary glands of patients with Sjogren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios. Arthritis Rheum 2005, 52:2751-2760.
25. Lantz M., Vondrichova T., Parikh H., Frenander C., Ridderstrale M., Asman P., et al. Over expression of immediate early genes in active Graves' ophthalmopathy. J Clin Endocrinol Metab 2005, 90:4784-4791.
26. Diamond M.S., Staunton D.E., Marlin S.D., Springer T.A. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell 1991, 65:961-971.
27. Salmaso C., Olive D., Pesce G., Bagnasco M. Costimulatory molecules and autoimmune thyroid diseases. Autoimmunity 2002, 35:159-167.
28. Hwang S.J., Ballantyne C.M., Sharrett A.R., Smith L.C., Davis C.E., Gotto A.M., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997, 96:4219-4225.
29. Aidinian G., Weiswasser J.M., Arora S., Abularrage C.J., Singh N., Sidawy A.N. Carotid plaque morphologic characteristics. Perspect Vasc Surg Endovasc Ther 2006, 18:63-70.